<DOC>
	<DOCNO>NCT02710656</DOCNO>
	<brief_summary>A randomized multicentric study endovascular treatment patient obstructive disease SFA ( superficial femoral artery ) popliteal artery .</brief_summary>
	<brief_title>Study Comparing Legflow Versus Bare Balloon Angioplasty Treatment Atherosclerotic Disease</brief_title>
	<detailed_description>This interventional study collect data treatment de novo lesion restenotic lesion . Restenotic lesion previously DCB ( drug coat balloon ) treat in-stent restenosis exclude study . The primary objective randomize study compare efficacy DCB ( Legflow - Cardionovum ) versus POBA treatment de novo lesion restenosis SFA popliteal artery ( segment P1 -P2 ) assess binary restenosis rate duplex ultrasonography 12 month . The secondary endpoint assessment immediate procedural outcome , distribution Rutherford , mortality , target lesion revascularization ( TLR ) , target extremity revascularization ( TER ) , amputation anklebrachial index ( ABI ) . For patient enrol , data collect 12 month procedure .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient must sign informed consent form prior indexprocedure . 2 . Patient must older 18 year . 3 . Patient Rutherford 2 , 3 4.. 4 . Target lesion occlusion ≥70 % stenosis ( visual estimate ) locate SFA popliteal artery ( P1 P2 ) . 5 . Maximum length target lesion 13 cm . 6 . Target lesion TASC A , B C. 7 . Target lesion de novo lesion restenotic lesion ( previously POBA treat , instent restenosis allow ) . 8 . Inflow artery free hemodynamically significant obstruction ( i.e . ≥ 50 % diameter stenosis ) . It allow treat inflow lesion indexprocedure result ≤ 30 % diameter stenosis ( treatment DCB DES allow ) . Treatment nontarget lesion target vessel allow nontarget lesion consider inflow lesion . 9 . Popliteal artery P3 segment ( knee popliteal artery ) free hemodynamically significant obstruction ( i.e . ≥ 50 % ) . Treatment lesion segment allow indexprocedure . 10 . At least 1 patent ( &lt; 50 % diameter stenosis ) belowtheknee vessel ( anterior tibial artery , posterior tibial artery peroneal artery ) till ankle confirm baseline angiography . 1 . Patient already include study ( recruitment contralateral leg allow ) . 2 . Patient known intolerance antiplatelet therapy contrast agent . 3 . Patient known sensitivity Paclitaxel . 4 . Patient pregnant patient intend become pregnant within 1 year indexprocedure . 5 . Patient take esomeprazole omeprazole . 6 . Patient serum creatinine &gt; 2.0 mg/dL renal dialysis . 7 . Patient suffers acute limb ischemia define sudden decrease limb perfusion cause potential threat limb viability . 8 . Patient life expectancy &lt; 2 year . 9 . Patient Rutherford 0 , 1 , 5 6 . 10 . Patient target lesion severely calcify ( grade 3 grade 4 ) . 11 . Patient TASC D lesion . 12 . Patient acute thrombus aneurysm target vessel . 13 . Patient target lesion cross guidewire . 14 . Target vessel treat previously DCB DES . 15 . Treatment outflow lesion indexprocedure . 16 . Patients significant disease 3 infrapopliteal vessel ( i.e . ≥ 50 % diameter stenosis vessel ) . 17 . Any scheduled surgery within 3 month indexprocedure would necessitate discontinuation clopidogrel . 18 . Patients previous bypass surgery involve SFA . 19 . Patient cirrhosis liver .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>SFA</keyword>
	<keyword>Poplitea</keyword>
	<keyword>Drug coat balloon</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Peripheral artery disease ( PAD )</keyword>
</DOC>